At a glance

Type

Peptide / related experimental research

Regulatory context

The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.

Evidence

Animal intervention results and human exercise-associated biomarker changes must not be described as a human peptide-treatment trial.

What it is

The original discovery report described a 16-amino-acid peptide encoded within a short mitochondrial DNA sequence. Cellular work linked its activity to metabolic pathways including AMPK. Finding an endogenous signalling molecule does not establish that administering more of it improves health. [1]

What the animal research shows

The 2015 study investigated metabolic effects in cells and mice, including insulin resistance associated with ageing or high-fat feeding. Treatment improved several metabolic measures in those models. The species, experimental diet and controlled conditions limit direct translation to a clinical treatment decision. [1]

What the human exercise study measured

In a 2021 report, ten healthy sedentary young men performed cycling exercise. Researchers measured naturally occurring MOTS-c in muscle and blood before and after exercise. Levels changed with exertion. The participants were not treated with MOTS-c: this was a physiological observation, not evidence that injections improve fitness. [2]

Why the mouse performance results are separate

The same publication tested administered MOTS-c in mice of different ages and reported changes in physical performance and muscle responses. It is important to keep that animal intervention separate from the human sampling experiment. Combining the two descriptions into “proven in humans” would misrepresent the study. [2]

What remains uncertain

Human efficacy, long-term safety, interactions and a clinically justified regimen for administered MOTS-c are not established by these sources. Exercise-associated changes do not show that replacing or augmenting the peptide reproduces exercise benefits. Claims about lifespan, diabetes treatment or fat loss need their own human evidence. [1] [2] [3]

Questions for your doctor

Was the cited evidence a treatment trial in humans, an animal experiment or a blood measurement? Which outcome matters for your health, and what established options address it? Ask for the exact formulation and the evidence relevant to the proposed route. [1] [2]

Safety and clinical context

FDA reports insufficient human exposure and safety information for administered MOTS-c, with potential immunogenicity and peptide-characterisation concerns. [3]

Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.